

Cross-over comparison of gabapentin and memantine as treatment for acquired nystagmus

Submission date 23/06/2009	Recruitment status No longer recruiting	☐ Prospectively registered ☐ Protocol
Registration date 01/09/2009	Overall study status Completed	☐ Statistical analysis plan ☒ Results
Last Edited 08/08/2019	Condition category Eye Diseases	☐ Individual participant data

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Dr R John Leigh

Contact details
Neurology (127W)
Louis Stokes Department
Veterans Affairs Medical Center
10701 East Boulevard
Cleveland, Ohio
United States of America
44106-1702
-
rjl4@case.edu

Additional identifiers

Protocol serial number
2003-057

Study information

Scientific Title

Comparison of gabapentin and memantine as treatment for acquired nystagmus: a double-blind cross-over study with each patient serving as their own control

Study objectives

To compare the therapeutic effects of gabapentin versus memantine at treatment for acquired nystagmus.

Ethics approval required

Old ethics approval format

Ethics approval(s)

1. Cleveland Veterans Affairs Medical Center Institutional Review Board approved on the 22nd June 2004
2. US Food and Drug Administration approved on the 8th January 2004 (ref: CPA #521)

Primary study design

Interventional

Study design

Double-blind cross-over study

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Nystagmus

Interventions

Gabapentin will be given at a starting dose of 1 capsule (300 mg) per day for 3 days; then 1 capsule twice per day for 3 days; then 1 capsule three times per day for 3 days, and finally 1 capsule four times per day (total = 1200 mg/day) for the final remaining 5 days. The final evaluation of vision and eye movements will be made during the 14th day of taking gabapentin. Memantine will be given at a starting dose of 1 capsule (10 mg) per day for 3 days; then 1 capsule twice per day for 3 days; then 1 capsule three times per day for 3 days, and finally 1 capsule four times per day (total = 40 mg/day) for the final remaining 5 days. The final evaluation of vision and eye movements will be made during the 14th day of taking memantine. Side effects of each medication will be monitored with a provision for holding at the maximum dose of the drug that the patient can tolerate for the duration of the study.

Intervention Type

Drug

Phase

Not Applicable

Drug/device/biological/vaccine name(s)

Gabapentin, memantine

Primary outcome(s)

1. Visual acuity of each eye, measured at far or near prior to, and on the final day of, treatment with each drug
2. Median eye speed, measured with the magnetic search coil technique, prior to, and on the final day of, treatment with each drug

Measured at the end of 14 days on each medicine.

Key secondary outcome(s)

The patient's overall assessment of whether either drug improves their vision and is generally well tolerated, measured at the end of 14 days on each medicine.

Completion date

22/06/2009

Eligibility

Key inclusion criteria

1. Patients with acquired nystagmus due to multiple sclerosis, stroke (brain stem) or cerebellar disease (such as Chiari malformation)
2. Medically stable
3. Able to give informed consent
4. Can understand and cooperate with the testing
5. Aged 18 years or older, both sexes

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Adult

Lower age limit

18 Years

Sex

All

Total final enrolment

10

Key exclusion criteria

1. Not able to understand or follow the instructions of each protocol
2. Too frail to sit in the vestibular chair during testing for the required period
3. Judged to be at risk for falls (many patients with poor balance adjust to this, and are not at risk of falls)
4. History of mental illness or confusion
5. Known to have an allergy to gabapentin or memantine
6. Pregnant, since the safety of memantine in pregnancy is unknown

Date of first enrolment

22/06/2004

Date of final enrolment

22/06/2009

Locations

Countries of recruitment

United States of America

Study participating centre

Neurology (127W)

Cleveland, Ohio

United States of America

44106-1702

Sponsor information

Organisation

National Eye Institute/National Institutes of Health (USA)

ROR

<https://ror.org/03wkg3b53>

Funder(s)

Funder type

Government

Funder Name

National Institutes of Health (NIH) (USA) (ref: R01-EY06717)

Alternative Name(s)

US National Institutes of Health, Institutos Nacionales de la Salud, NIH, USNIH

Funding Body Type

Government organisation

Funding Body Subtype

National government

Location

United States of America

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	01/05/2010	08/08/2019	Yes	No